Dinoprost tromethamine salt| CAS 38562-01-5

Cas No.:	38562-01-5
Chemical Name:	Dinoprost tromethamine salt
Synonyms:	Prostaglandin F2a tris salt;Prostaglandin F2-alpha tromethamine salt;(5Z,9a,11a,13E,15S)-9,11,15-Trihydroxyprosta-5,13-dienoic acid tris salt;Dinoprost;Dinorprost tromethamine;PGF2α (Prostaglandin F2α);Prostaglandin F2α;Prostaglandin F2α (tromethamine salt);Prostaglandin F2α Tr;Prostaglandin F2α tris salt;Prostaglandin F2α Tromethamine Salt;Dinoprost tromethamine;Dinoprost trometamol;PGF2α THAM;Prostaglandin F2a tromethamine salt;Prostaglandin F2α THAM;(5Z,9α,11α,13E,15S)-9,11,15-Trihydroxyprosta-5,13-dienoic acid tris salt;PGF2α−Tris;Dinolytic;Zinoprost;PGF2-alpha tham;Prostalmon F;Prostin F2 alpha;Lutalyse;PGF2alpha THAM;Pronalgon F;Prostaglandin F2alpha tham;Panacelan F tromethamine salt;Prostaglandin F2-alpha THAM;Prostaglandin F2a tromethamine;Dinoprost, trometamol salt;THAM PGF2-alpha;Ensaprost;Lutalyse (Veterinary);PGF2-alpha tris salt;PGF2-alpha tromethamine;Enzaprost F compd. with trisamine;PGF2-alpha tromethamine salt;Protaglandin F2-alpha-tham salt;Prostaglandi;CID 126963607;Dinoprost tromethamine salt;Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-, (5Z,9α,11α,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1);Prostaglandin F2α THAM salt;Prostaglandin F2α tris(hydroxymethyl)aminomethane;Prostaglandin F2α tris(hydroxymethyl)aminomethane salt;Prostaglandin F2α tromethamine;Prostaglandin F2α tromethamine salt;Prostaglandin F2α-tham;THAM PGF2α
SMILES:	O([H])[C@@]1([H])C([H])([H])[C@]([H])([C@]([H])(C([H])=C([H])[C@]([H])(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])O[H])[C@]1([H])C([H])([H])C([H])=C([H])C([H])([H])C([H])([H])C([H])([H])C(=O)O[H])O[H].O([H])C([H])([H])C(C([H])([H])O[H])(C([H])([H])O[H])N([H])[H]
Formula:	C₂₄H₄₅NO₈
M.Wt:	475.62
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	Dinoprost(Prostaglandin F2α) tromethamine salt is a naturally occurring prostaglandin used in medicine to induce labor and as an abortifacient.
References:	[1]. Sharma I, et al. Role of 8-iso-prostaglandin F2alpha and 25-hydroxycholesterol in the pathophysiology of endometriosis. Fertil Steril. 2010 Jun;94(1):63-70. [2]. Coulthard G, et al. Stereocontrolled organocatalytic synthesis of prostaglandin PGF2α in seven steps. Nature. 2012 Sep 13;489(7415):278-81.

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.